Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.

J Genet Eng Biotechnol · 2025 · PMC12514579 · PMID 41386839

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

For instance, A2ML1 exhibited a log2 fold change (log2FC) of 3.859 in TCGA and 0.616 in METABRIC, with highly significant adjusted p-values (< 2.00E-73 and 9.03E-76, respectively).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.